Номер журнала: 
Год издания: 

А. Ешихиса, Ю. Сато, С. Ватанабе, Т. Екокава, Т. Сато, С. Сузуки, М. Оикава, А. Кобаяши, Я. Такеиши Фукусимский медицинский университет, Япония E-mail: yoshihis@fmu.ac.jp

Эффективные методы лечения больных с сердечной недостаточностью (СН) ишемической этиологии пока полностью не определены. Никорандил – мощное средство расширения коронарных сосудов, антиангинальное средство, потенциально эффективен в снижении смертности больных с СН ишемической этиологии.
Ключевые слова: 
кардиология, сердечная недостаточность ишемической этиологии, никорандил, сердечная смертность, прогноз

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Ponikowski P., Voors A., Anker S. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. – 2016; 37 (27): 2129–200.
  2. Yancy C., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines // J. Am. Coll. Cardiol. – 2013; 62 (16): e147–239.
  3. Fonarow G., Albert N., Curtis A. et al. Incremental reduction in risk of death associated with use of guidelinerecommended therapies in patients with heart failure: a nested casecontrol analysis of IMPROVE HF // J. Am. Heart Assoc. – 2012; 1 (1): 16–26.
  4. Khatibzadeh S., Farzadfar F., Oliver J. et al. Worldwide risk factors for heart failure: a systematic review and pooled analysis // Int. J. Cardiol. – 2013; 168 (2): 1186–94.
  5. Felker G., Shaw L., O'Connor C. A standardized definition of ischemic cardiomyopathy for use in clinical research // J. Am. Coll. Cardiol. – 2002; 39 (2): 210–8.
  6. Smith P., Puskas J., Ascheim D. et al. Surgical treatment of moderate ischemic mitral regurgitation // N. Engl. J. Med. – 2014; 371 (23): 2178–88.
  7. Mohr F., Morice M., Kappetein A. et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial // Lancet. – 2013; 381 (9867): 629–38.
  8. Deja M., Grayburn P, Sun B. et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial // Circulation. – 2012; 125 (21): 2639–48.
  9. Velazquez E., Lee K., Deja M. et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction // N. Engl. J. Med. – 2011; 364 (17): 1607–16.
  10. Petrie M., Jhund P., She L. et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction:an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure) // Circulation. – 2016; 134 (18): 1314–24.
  11. Luo B., Wu P., Bu T. et al. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and metaanalysis of the literature // Int. J. Cardiol. – 2014; 176 (3): 661–9.
  12. McKee P., Castelli W., McNamara P., et al. The natural history of congestive heart failure: the Framingham study // N. Engl. J. Med. – 1971; 285 (26): 1441–6.
  13. Zhao F., Chaugai S., Chen P. et al. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis // Cardiovasc. Ther. – 2014; 32 (6): 283–96.
  14. Kasama S., Toyama T., Iwasaki T. et al. Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching // Eur. J. Nucl. Med. Mol. Imaging. – 2014; 41 (1): 144–54.